GRP
CERE

Global Retirement Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Global Retirement Partners’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12
Closed -$491 – 3680
2024
Q2 		$491 Hold
12
– – ﹤0.01% 3294
2024
Q1 		$507 Hold
12
– – ﹤0.01% 3126
2023
Q4 		$511 Hold
12
– – ﹤0.01% 3078
2023
Q3 		$244 Hold
12
– – ﹤0.01% 3093
2023
Q2 		$381 Hold
12
– – ﹤0.01% 3005
2023
Q1 		$383 Sell
12
-9
-43% -$264 ﹤0.01% 2980
2022
Q4 		$662 Buy
21
+9
+75% +$254 ﹤0.01% 2694
2022
Q3 		$0 Hold
12
– – ﹤0.01% 3044
2022
Q2 		$0 Hold
12
– – ﹤0.01% 2929
2022
Q1 		$0 Buy
+12
New +$350 ﹤0.01% 2822

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Global Retirement Partners's CERE Position: Q3 2024 in Review

Global Retirement Partners sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 12 shares — an estimated $491 sold.

Global Retirement Partners first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $662 in Q4 2022. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Global Retirement Partners reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Global Retirement Partners sold 12 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $491.
  • Global Retirement Partners first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • Global Retirement Partners's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $662 in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Global Retirement Partners's 13F filing for Q3 2024, filed 16 Oct 2024.